ArticleClinical genitourinary cancer2022
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Open access · greenAbstract read
In one paragraph
Article in Clinical genitourinary cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.Journal for immunotherapy of cancer · 2023Trial
- Immune Phenotype in Urothelial Carcinoma: From Tumor Biology to Therapeutic Stratification.Cancers · 2026Review
- Article
- Breaking the immune "cold niche" in bone metastasis: core mechanisms of the multidimensional interwoven regulatory network and precision breakthrough strategies.Molecular cancer · 2026Review
- First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma.JAMA network open · 2026Article
- Site-specific heterogeneity in treatment response among patients with metastatic bladder cancer: implications for oligometastatic disease-a retrospective cohort study.Translational andrology and urology · 2026Article
- Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma.IJU case reports · 2026Article
- Cannonball metastases as an initial presentation of urothelial bladder carcinoma: a case report and literature review.Urology case reports · 2026Article
- A Review of the Latest Evidence on Prognostic Factors in Locally Advanced and Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.Medicina (Kaunas, Lithuania) · 2025Review
- Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma.Cancer immunology, immunotherapy : CII · 2025Article
- Article
- Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.Cancer immunology, immunotherapy : CII · 2024Observational
- Article
- Patients with Extensive-Stage Small Cell Lung Cancer Harboring Less Than 4 Metastatic Sites May Benefit from Immune Checkpoint Inhibitor Rechallenge by Reshaping Tumor Microenvironment.ImmunoTargets and therapy · 2024Article
- Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.Clinical and experimental medicine · 2023Article
- Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.Clinical genitourinary cancer · 2023Article
- Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case-Control Study.Targeted oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 20 institutions in 7 countries.
Dimitrios MakrakisDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Rafee TalukderDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Genevieve Ihsiu LinDepartment of Epidemiology, University of Washington, Seattle, WA.
Leonidas N DiamantopoulosDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA.
Scott DawseyDepartment of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
Shilpa GuptaDepartment of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
Lucia Carril-AjuriaDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Daniel CastellanoDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Ivan de KouchkovskyDivision of Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA.
Vadim S KoshkinDivision of Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA.
Joseph J ParkDivision of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI.
Ajjai AlvaDivision of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI.
Mehmet A BilenWinship Cancer Institute of Emory University, Atlanta, GA.
Tyler F StewartDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.
Rana R McKayDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.
Nishita TripathiDivision of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT.
Neeraj AgarwalDivision of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT.
Naomi Vather-WuDepartment of Medicine, University of Iowa, Iowa City, IA.
Yousef ZakhariaDivision of Oncology, Department of Medicine, University of Iowa, Iowa City, IA.
Rafael Morales-BarreraVall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Michael E DevittDivision of Hematology/Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA.
Alessio CortelliniDepartment of Surgery and Cancer, Imperial College London, London, UK.
Claudia Angela Maria FulgenziDepartment of Surgery and Cancer, Imperial College London, London, UK.
David J PinatoDepartment of Surgery and Cancer, Imperial College London, London, UK.
Ariel NelsonDivision of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Christopher J HoimesDivision of Medical Oncology, Seidman Cancer Center at Case Comprehensive Cancer Center, Cleveland, OH; Division of Medical Oncology, Duke University, Durham, NC.
Kavita GuptaDepartments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY.
Benjamin A GartrellDepartments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY.
Alex SankinDepartments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY.
Abhishek TripathiStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Roubini ZakopoulouDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Aristotelis Bamias2nd Propaedeutic Dept of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Jure MurgicDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb.
Ana FröbeDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb; School of Dental Medicine, Zagreb, Croatia.
Alejo Rodriguez-VidaMedical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain.
Alexandra DrakakiDivision of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Sandy LiuDivision of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Eric LuDivision of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Vivek KumarDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Giuseppe Di LorenzoOncology University of Molise and Medical Oncology ASL, Salerno, Italy.
Monika JoshiDivision of Hematology/Oncology, Department of Medicine, Penn State Cancer Institute, Hershey, PA.
Pedro Isaacsson-VelhoDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Division of Oncology, Hospital Moinhos de Vento, Porto Alegre, Brazil.
Lucia Alonso BuznegoHospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain.
Ignacio DuranHospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain.
Marcus MosesDeming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA.
Albert JangDeming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA.
Pedro BarataDeming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA.
Guru SonpavdeGenitourinary Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Evan Y YuDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Robert Bruce MontgomeryDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Petros GrivasDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: pgrivas@uw.edu.
Ali Raza KhakiDivision of Oncology, Department of Medicine, Stanford University, Palo Alto, CA. Electronic address: alikhaki@stanford.edu.
University of Washington Medical Center · USImperial College London · GBMontefiore Medical Center · USTulane University · USUniversity of California, Los Angeles · USCleveland Clinic · USHospital Universitario 12 De Octubre · ESInstituto de Investigación Marqués de Valdecilla · ESNational and Kapodistrian University of Athens · GRUniversity of California San Diego · USUniversity of California, San Francisco · USUniversity of Iowa · USUniversity of Michigan · USUniversity of Utah · USBrigham and Women's Hospital · USEmory University · USHarvard University · USHospital Del Mar · ESHospital Moinhos de Vento · BRMedical College of Wisconsin · US
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9MTransform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0MTRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2MCancer Research UKDepartment of HealthNCATS NIH HHS UL1 TR002319NCI NIH HHS P30 CA023100NCI NIH HHS T32 CA009515Wellcome TrustWellcome Trust PS3416
Abstract
backgroundSites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors (ICI). We hypothesized that presence of liver/bone metastases would be associated with worse outcomes with ICI.
methodsWe identified a retrospective cohort of patients with aUC across 26 institutions, collecting demographics, clinicopathological, treatment, and outcomes information. Outcomes were compared with logistic (observed response rate; ORR) and Cox (progression-free survival; PFS, overall survival; OS) regression between patients with/without metastasis beyond lymph nodes (LN) and those with/without bone/liver/lung metastasis. Analysis was stratified by 1st or 2nd
resultsWe identified 917 ICI-treated patients: in the 1st line, bone/liver metastases were associated with shorter PFS (Hazard ratio; HR: 1.65 and 2.54), OS (HR: 1.60 and 2.35, respectively) and lower ORR (OR: 0.48 and 0.31). In the 2nd
conclusionBone and/or liver metastases were associated with worse, while LN-confined metastases were associated with better outcomes in patients with aUC receiving ICI. These findings in a large population treated outside clinical trials corroborate data from trial subset analyses.
Indexed as
Carcinoma, Transitional CellLiver NeoplasmsUrinary Bladder NeoplasmsHumansImmune Checkpoint InhibitorsRetrospective StudiesImmune Checkpoint InhibitorsAdvanced urothelial carcinomaBladder cancerImmune checkpoint inhibitorsMetastatic cancerOutcomes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.